<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ibrutinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ibrutinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ibrutinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="91588" href="/d/html/91588.html" rel="external">see "Ibrutinib: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="139668" href="/d/html/139668.html" rel="external">see "Ibrutinib: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F54945785"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Imbruvica Withdrawal of Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications</span>
<span class="collapsible-date">April 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">AbbVie announced on April 6, 2023, the intent to voluntarily withdraw, in the United States, accelerated Imbruvica (ibrutinib) approvals for mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy and for marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least 1 prior anti-CD20−based therapy. This does not affect other approved indications for Imbruvica. This voluntary action is due to requirements related to the accelerated approval status granted by the FDA for MCL and MZL. Health care providers should consider the withdrawal of these indications in their treatment plans for patients with MCL and MZL currently taking Imbruvica.</p>
<p style="text-indent:0em;">Further information may be found at https://news.abbvie.com/news/press-releases/update-on-imbruvica-ibrutinib-us-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications.htm.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F22769660"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Imbruvica</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871683"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Imbruvica</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F22688543"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent;</li>
<li>
                        Antineoplastic Agent, Bruton Tyrosine Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F22802477"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Consider antimicrobial prophylaxis (according to standard of care) in patients at risk for opportunistic infection. Evaluate the risks and benefits of withholding ibrutinib for 3 to 7 days prior to and after surgery, depending on the procedure type and risk of bleeding.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d69dfbae-4438-4fd5-82d1-89796bed4188">Chronic lymphocytic leukemia/small lymphocytic lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia/small lymphocytic lymphoma (including chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion):</b>
<b>Oral:</b> 420 mg once daily (either as monotherapy, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24881631','lexi-content-ref-26655421','lexi-content-ref-30522969','lexi-content-ref-31365801','lexi-content-ref-35427411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24881631','lexi-content-ref-26655421','lexi-content-ref-30522969','lexi-content-ref-31365801','lexi-content-ref-35427411'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>F</i>
<i>ixed duration of treatment in previously untreated disease (off-label combination): </i>
<b>Oral:</b> 420 mg once daily on days 1 to 28 every 28 days (as a single agent) for 3 cycles, followed by 420 mg once daily on days 1 to 28 every 28 days (in combination with venetoclax [venetoclax is ramped up in cycle 4]) for an addition 12 cycles, for a total of 15 ibrutinib cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25138588','lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25138588','lexi-content-ref-34618601'])">Ref</a></span>). In one study, patients who completed 15 cycles (3 lead in cycles plus 12 combination cycles) were administered 1 additional cycle during which minimal residual disease status and tumor response were assessed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34618601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34618601'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="903d3a32-cdb7-4a20-b97c-5485949c8160">Graft-versus-host disease, chronic, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic, refractory: Oral:</b> 420 mg once daily; continue until chronic graft-versus-host disease (cGVHD) disease progression, recurrence of underlying malignancy, or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924018'])">Ref</a></span>). When cGVHD treatment is no longer required, discontinue ibrutinib based on medical assessment of patient.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia:</b>
<b>Oral:</b> 420 mg once daily (either as monotherapy or in combination with rituximab); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29856685','lexi-content-ref-25853747','lexi-content-ref-32931398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29856685','lexi-content-ref-25853747','lexi-content-ref-32931398'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is not administered at the scheduled time, it may be administered as soon as possible on the same day; return to normal schedule the following day. Do not administer extra doses to make up for the missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990747"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> There have been reports of tumor lysis syndrome secondary to ibrutinib treatment in patients with underlying kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28714377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28714377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥25 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, &lt;10% of ibrutinib is excreted by the kidneys (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25488930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25488930'])">Ref</a></span>); therefore, no dosage adjustment likely to be necessary. A single case report describes the successful use of ibrutinib in a patient with severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29071051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29071051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36278298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36278298'])">Ref</a></span>): <b>Oral:</b> Based on ibrutinib pharmacokinetic characteristics and case reports describing the successful use of ibrutinib in patients on hemodialysis, no dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28508526','lexi-content-ref-33938097','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28508526','lexi-content-ref-33938097','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: Oral: </b>There are no data describing ibrutinib use in patients on peritoneal dialysis (has not been studied); however, no dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>
<b>Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988129"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>B-cell malignancies: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Turcotte-Pugh class A): Reduce dose to 140 mg once daily. Monitor more frequently for toxicities; may require treatment interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Turcotte-Pugh class B): Reduce dose to 70 mg once daily. Monitor more frequently for toxicities; may require treatment interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Turcotte-Pugh class C): Avoid ibrutinib use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic graft-versus-host disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Total bilirubin &gt;1.5 to 3 times ULN (unless of nonhepatic origin or due to Gilbert syndrome): Reduce dose to 140 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Total bilirubin &gt;3 times ULN (unless of nonhepatic origin or due to Gilbert syndrome): Avoid ibrutinib use.</p></div>
<div class="block dot drugH1Div" id="F22802481"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommended ibrutinib dosage modifications for adverse reactions following improvement to grade 1 or baseline (recovery):</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Ibrutinib Dose Modification for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Occurrence</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic graft-versus-host disease, and Waldenström macroglobulinemia </b></p>
<p style="text-indent:0em;text-align:center;">
<b>(Initial dose: 420 mg once daily)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>For other grade 4 nonhematologic toxicities, evaluate risks versus benefits prior to resuming ibrutinib.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:center;">Cardiac arrhythmias: Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">First occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Restart at 280 mg once daily (after assessment of risks vs benefits).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Second occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Cardiac arrhythmias: Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">First occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:center;">Heart failure: Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">First occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Restart at 280 mg once daily (after assessment of risks vs benefits).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Second occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Restart at 140 mg once daily (after assessment of risks vs benefits).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Third occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Heart failure: Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">First occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Initiate or adjust antihypertensive therapy as appropriate. If ≥ grade 3 hypertension occurs, follow dosage modifications below for other grade 3 or 4 nonhematologic toxicities.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">Infection</p></td>
<td align="center">
<p style="text-indent:0em;">Evaluate and manage appropriately.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">Tumor lysis syndrome</p></td>
<td align="center">
<p style="text-indent:0em;">Manage appropriately.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:center;">Other toxicities:</p>
<ul>
<li>
<p style="text-indent:0em;">Other grade 3 or 4 nonhematological toxicities<sup>a</sup></p></li>
<li>
<p style="text-indent:0em;">Grade 3 or 4 neutropenia with infection or fever</p></li>
<li>
<p style="text-indent:0em;">Grade 4 hematological toxicities</p></li></ul></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">First occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Restart at 280 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Second occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Restart at 140 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Third occurrence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue ibrutinib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F22802478"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57211254"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139668" href="/d/html/139668.html" rel="external">see "Ibrutinib: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pediatric dosing in both <b>mg/m<sup>2</sup></b> and mg (fixed dose); use caution during dose calculations. Consider antimicrobial prophylaxis (according to standard of care) in patients at risk for opportunistic infection. Evaluate the risks and benefits of withholding ibrutinib for 3 to 7 days prior to and after surgery, depending on the procedure type and risk of bleeding.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="903d3a32-cdb7-4a20-b97c-5485949c8160">Graft-versus-host disease, chronic, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic (cGVHD), refractory: Note:</b> Continue ibrutinib therapy until cGVHD disease progression, recurrence of underlying malignancy, or unacceptable toxicity. When cGVHD treatment is no longer required, discontinue ibrutinib based on medical assessment of patient.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:6em;">BSA-directed dosing: Oral: 240 <b>mg/m<sup>2</sup></b> once daily; maximum dose: 420 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-banded dosing: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Weight-banded Dosing for Children &lt;12 Years of Age</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>BSA (m<sup>2</sup></b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Oral Suspension </b>(70 m<b>g/mL) Daily Dose (mg) </b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Capsule/Tablet </b>
<b>Daily Dose (mg)</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;0.3 to 0.4 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">84 mg</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;0.4 to 0.5 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">105 mg</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;0.5 to 0.6 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">133 mg</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;0.6 to 0.7 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">154 mg</p></td>
<td align="left"></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;0.7 to 0.8 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">182 mg</p></td>
<td align="left">
<p style="text-indent:0em;">210 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;0.8 to 0.9 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">203 mg</p></td>
<td align="left">
<p style="text-indent:0em;">210 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;0.9 to 1 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">231 mg</p></td>
<td align="left">
<p style="text-indent:0em;">210 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;1 to 1.1 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">252 mg</p></td>
<td align="left">
<p style="text-indent:0em;">280 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;1.1 to 1.2 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">280 mg</p></td>
<td align="left">
<p style="text-indent:0em;">280 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;1.2 to 1.3 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">301 mg</p></td>
<td align="left">
<p style="text-indent:0em;">280 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;1.3 to 1.4 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">322 mg</p></td>
<td align="left">
<p style="text-indent:0em;">350 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;1.4 to 1.5 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">350 mg</p></td>
<td align="left">
<p style="text-indent:0em;">350 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;1.5 to 1.6 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">371 mg</p></td>
<td align="left">
<p style="text-indent:0em;">350 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;1.6 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">420 mg</p></td>
<td align="left">
<p style="text-indent:0em;">420 mg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 420 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pediatric dosing is in both <b>mg/m<sup>2</sup></b>and mg; please review dosing units closely in table.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Ibrutinib Dose Modification for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Adverse Reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Occurrence</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Ages 1 to &lt;12 Years</b></p>
<p style="text-indent:0em;text-align:left;">
<b>(Based on Starting Dose ~240 mg/m<sup>2</sup>)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Age ≥12 Years </b></p>
<p style="text-indent:0em;text-align:left;">
<b> (Starting Dose: 420 mg)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>For other grade 4 nonhematologic toxicities, evaluate risks versus benefits prior to resuming ibrutinib.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cardiac arrhythmias: Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 160 <b>mg/m<sup>2</sup></b> once daily (after assessment of risks vs benefits).</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 280 mg once daily (after assessment of risks vs benefits).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiac arrhythmias: Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Heart failure: Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 160 <b>mg/m<sup>2</sup></b> once daily (after assessment of risks vs benefits).</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 280 mg once daily (after assessment of risks vs benefits).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 80 <b>mg/m<sup>2</sup></b> once daily (after assessment of risks vs benefits).</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 140 mg once daily (after assessment of risks vs benefits).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Third</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart failure: Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Initiate or adjust antihypertensive therapy as appropriate. If ≥ grade 3 hypertension occurs, follow dosage modifications below for other grade 3 or 4 nonhematologic toxicities.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Other toxicities:</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">• Other grade 3 or 4 nonhematological toxicities<sup>a</sup></p>
<p style="text-indent:0em;text-align:left;">• Grade 3 or 4 neutropenia with infection or fever</p>
<p style="text-indent:0em;text-align:left;">• Grade 4 hematological toxicities</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 160 <b>mg/m<sup>2</sup></b> once daily (after assessment of risks vs benefits).</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 280 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 80 <b>mg/m<sup>2</sup></b> once daily (after assessment of risks vs benefits).</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hold dose until improved to Grade 1 or baseline (recovery). Restart at 140 mg once daily.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Third</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue ibrutinib.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F57211438"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, renal excretion is minimal and drug exposure is not altered in patients with mild to moderate impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;25 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease requiring dialysis: There are no dosage adjustments provided in the manufacturer's labeling (no data available).</p></div>
<div class="block dohp drugH1Div" id="F57211439"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Total bilirubin &gt;1.5 to 3 times ULN (unless nonhepatic origin or Gilbert syndrome):</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years: Oral: 80 <b>mg/m<sup>2</sup></b>once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 140 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Total bilirubin &gt;3 times ULN (unless nonhepatic origin or Gilbert syndrome): Children and Adolescents: Avoid use.</p></div>
<div class="block arsc drugH1Div" id="F57192480"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious (and some fatal) cardiac arrhythmias and <b>heart failure</b> have occurred with ibrutinib, including ≥ grade 3 <b>atrial fibrillation</b>, <b>atrial flutter</b>, heart failure, and <b>ventricular tachyarrhythmias</b>. In an analysis utilizing the international pharmacovigilance database, ibrutinib was associated with higher reporting of cardiovascular adverse events, including heart failure, <b>supraventricular cardiac arrhythmia,</b>
<b>ventricular arrhythmia</b>, <b>cardiac conduction disorder</b>, <b>hypertension</b>, and CNS hemorrhagic or ischemic events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>). Events have occurred in patients with and without preexisting cardiac risk factors. <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Heart failure: May be caused by off-target blockade of HER2 and/or phosphoinositide 3-kinase-protein kinase B (PI3K–AKT) pathways. Supraventricular arrhythmias: May occur due to blockade of PI3K-AKT pathway, leading to activation of the late sodium current (INa-L) in atrial cells. Ventricular arrhythmias: Not clearly established; does not appear to be caused by QTc prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; Heart failure: Median ~2 months (interquartile range: ~3 weeks to 5 months). Supraventricular arrhythmias: Median ~2.5 months (interquartile range: ~1 to 6.5 months). Ventricular arrhythmias: Median ~2 months (interquartile range: ~1 to 5 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (&gt;70 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiac arrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiac disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute infections</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent cardiotoxic agents</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects &amp; infections</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Grade 3 and 4 <b>neutropenia</b>, <b>thrombocytopenia</b>, and<b> anemia</b> occurred during clinical studies in patients who received single-agent ibrutinib for B-cell malignancies. An increased risk of opportunistic <b>infection</b>, including <b>pneumonia due to <i>Pneumocystis jirovecii</i></b> (PJP), have occurred in patients treated with ibrutinib. <b>Lymphocytosis</b> (≥50% increase from baseline) and leukostasis may occur upon therapy initiation. Some patients who developed lymphocytosis (lymphocytes &gt;400,000/mcL) developed <b>intracranial hemorrhage</b>, lethargy, <b>headache</b>, and abnormal gait; however, some cases may have been associated with disease progression. Lymphocytosis resolves within 8 weeks (mantle cell lymphoma) or 14 weeks (chronic lymphocytic leukemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28775119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28775119'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to mechanism of action; inhibits B-cell function, increasing the risk for opportunistic infections, such as PJP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28775119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28775119'])">Ref</a></span>). Lymphocytosis is caused by disruption of integrin-mediated adhesion and homing of malignant B-cells, leading to release from the lymphoid microenvironment into systemic circulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28775119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28775119'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Pancytopenia: Varied; within the initial months after initiation. Lymphocytosis: Intermediate; within the first few weeks/first month of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28775119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28775119'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemorrhage</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major hemorrhage</b> (and some fatal) has occurred with therapy, including ≥ grade 3, serious, or any CNS events (eg, <b>intracranial hemorrhage</b> [including <b>subdural hematoma</b>]), <b>gastrointestinal hemorrhage</b>, <b>hematuria</b>, and <b>postprocedural hemorrhage</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>). Bleeding events of any grade, including mucocutaneous bleeding (eg, <b>bruise</b>, <b>petechia</b>), have also occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26430171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26430171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to mechanism of action; ibrutinib has anti-platelet effects, likely mediated by targeting von Willebrand factor (vWF)-glycoprotein Ib and collagen-glycoprotein VI signal transduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; often corresponding to thrombocytopenia. Median onset of CNS hemorrhagic events ~2 months (interquartile range: ~3 weeks to 6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent anticoagulant and/or antiplatelet therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower baseline Factor VIII &amp; vWF activity levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26430171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26430171'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension</b> has commonly been reported in patients treated with ibrutinib. Hypertension may require initiation of antihypertensive therapy or adjustment of existing antihypertensive regimen. New or worsening hypertension has been associated with a higher risk of subsequent major adverse cardiovascular events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; may occur due to downregulation of nitric oxide formation and endothelial dysfunction. Another postulated mechanism is inhibition of phosphoinositide-3-protein kinase B (PI3K)-AKT pathway, including indirect downregulation of PI3K-p110α, leading to vascular tissue fibrosis and cellular remodeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median ~5.5 months (interquartile range ~3 weeks to 9 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31558250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31558250'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic lymphocytic leukemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent anthracycline use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent CYP3A4 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582362'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Progressive multifocal encephalopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Progressive multifocal leukoencephalopathy</b> is a rare and often fatal infection of the cerebrum caused by the John Cunningham (JC) virus. Patients present with rapidly progressive neurological symptoms including, but not limited to confusion, speech or gait disorders, and urinary incontinence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27456945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27456945'])">Ref</a></span>). Diagnosis may be delayed due to lack of awareness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30045034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30045034'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; may be related to inhibition of B-cell function, allowing JC virus reactivation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30045034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30045034'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; ranges from ~1 month to 2 years after initiation in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27649938','lexi-content-ref-30045034','lexi-content-ref-27456945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27649938','lexi-content-ref-30045034','lexi-content-ref-27456945'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other B-cell–depleting agents (eg, rituximab, brentuximab, fludarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27649938','lexi-content-ref-27456945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27649938','lexi-content-ref-27456945'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic lymphocytic leukemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27649938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27649938'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Second primary malignancies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with Bruton's tyrosine kinase inhibitors (BTKi), including ibrutinib, have developed <b>second primary malignant neoplasm,</b> such as nonmelanoma <b>skin carcinoma </b>and other non-skin <b>carcinoma</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32704159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32704159'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; may be related to immune dysfunction due to BTK inhibition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32704159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32704159'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to diagnosis 26 months (range: ~12 days to ≥7 years) after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32704159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32704159'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic lymphocytic leukemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32704159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32704159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32704159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32704159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher baseline platelet count (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32704159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32704159'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F22806759"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for ibrutinib monotherapy in adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (children, adolescents, and adults: 11% to 16%; cumulative rate increased over time)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, peripheral edema (12% to 22%), sinus tachycardia (children, adolescents, and adults: 11%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorambucil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Chlorambucil)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children, adolescents, and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥12 years: 420 mg orally once daily, 1 to 12 years: 240 mg/m<sup>2</sup> orally once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic graft-versus-host disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">47</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">132</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Waldenström macroglobulinemia and marginal zone lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (children, adolescents, and adults: 13%), skin infection (children, adolescents, and adults: 15% to 18%), skin rash (children, adolescents, and adults: 12% to 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (children, adolescents, and adults: 12% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children, adolescents, and adults: 13% to 23%), constipation (12% to 22%), decreased appetite (16%), diarrhea (children, adolescents, and adults: 28% to 59%; grades ≥3: 2% to 10%), dyspepsia (11% to 12%), gastroesophageal reflux disease (12%), nausea (children, adolescents, and adults: 19% to 26%; grades ≥3: 1% to 4%), stomatitis (children, adolescents, and adults: 14% to 29%; grades ≥3: 1% to 9%), vomiting (children, adolescents, and adults: 13% to 19%; grades ≥3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (10% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (children, adolescents, and adults: ≥20%; grades 3/4: 3%), bruise (11% to 51%; grades ≥3: 1% to 2%), hemorrhage (children, adolescents, and adults: 17% to 28%; including major hemorrhage, gastrointestinal hemorrhage, hematuria, and postprocedural hemorrhage), hypogammaglobulinemia (children, adolescents, and adults: 11%), lymphocytosis (66%), neutropenia (children, adolescents, and adults: ≥30%; grades 3/4: 2% to 23%),<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 2</a>)</span><span class="table-link" style="display:none;">Neutropenia</span> petechia (children, adolescents, and adults: 13% to 16%), thrombocytopenia (children, adolescents, and adults: ≥20%; grades 3/4: 1% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Thrombocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-thrombocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-thrombocytopenia')">table 3</a>)</span><span class="table-link" style="display:none;">Thrombocytopenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children, adolescents, and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥12 years: 420 mg orally once daily, 1 to 12 years: 240 mg/m<sup>2</sup> orally once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic graft-versus-host disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">47</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic graft-versus-host disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">42</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chlorambucil: 12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">132</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ofatumumab: 8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">195</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">191</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Waldenström macroglobulinemia and marginal zone lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">B-cell malignancies</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">645</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Thrombocytopenia" frame="border" id="lexi-content-thrombocytopenia" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Thrombocytopenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Waldenström macroglobulinemia and marginal zone lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">94</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ofatumumab: 3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">195</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">191</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chlorambucil: 3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Chronic lymphocytic leukemia/small lymphocytic lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">132</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">B-cell malignancies</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">645</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (children, adolescents, and adults: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including bacterial infection, fungal infection, and viral infection [reactivation of HBV]), sepsis (children, adolescents, and adults: 10% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (14%), chills (12%), dizziness (11% to 20%), falling (17%), fatigue (18% to 57%), headache (children, adolescents, and adults: 12% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (16% to 24%), muscle spasm (11% to 29%), musculoskeletal pain (children, adolescents, and adults: 14% to 36%), osteonecrosis (children, adolescents, and adults: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (≤13%), decreased visual acuity (≤11%), dry eye syndrome (17%), increased lacrimation (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children, adolescents, and adults: 13% to 22%), dyspnea (10% to 12%), oropharyngeal pain (14%), pneumonia (children, adolescents, and adults: 12% to 23%), sinusitis (11% to 22%), upper respiratory tract infection (16% to 47%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children, adolescents, and adults: 12% to 30%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (≤8%)<span class="lexi-table-link-container"> (<a aria-label="Atrial Fibrillation table link" class="lexi-table-link" data-table-id="lexi-content-atrial-fibrillation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-atrial-fibrillation')">table 4</a>)</span><span class="table-link" style="display:none;">Atrial Fibrillation</span>, atrial flutter (≤8%)<span class="lexi-table-link-container"> (<a aria-label="Atrial Flutter table link" class="lexi-table-link" data-table-id="lexi-content-atrial-flutter" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-atrial-flutter')">table 5</a>)</span><span class="table-link" style="display:none;">Atrial Flutter</span>, heart failure (2%)<span class="lexi-table-link-container"> (<a aria-label="Heart Failure table link" class="lexi-table-link" data-table-id="lexi-content-heart-failure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-heart-failure')">table 6</a>)</span><span class="table-link" style="display:none;">Heart Failure</span>, ventricular tachyarrhythmia (1%; including ventricular arrhythmia, ventricular fibrillation, cardiac [ventricular] flutter, ventricular premature contractions, ventricular tachycardia)<span class="lexi-table-link-container"> (<a aria-label="Ventricular Tachyarrhythmia table link" class="lexi-table-link" data-table-id="lexi-content-ventricular-tachyarrhythmia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ventricular-tachyarrhythmia')">table 7</a>)</span><span class="table-link" style="display:none;">Ventricular Tachyarrhythmia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Atrial Fibrillation" frame="border" id="lexi-content-atrial-fibrillation" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Atrial Fibrillation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Control</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Control)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Combined term with atrial flutter</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Atrial Flutter" frame="border" id="lexi-content-atrial-flutter" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Atrial Flutter</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Control</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Control)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Combined term with atrial fibrillation</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Heart Failure" frame="border" id="lexi-content-heart-failure" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Heart Failure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Control</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Control)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ventricular Tachyarrhythmia" frame="border" id="lexi-content-ventricular-tachyarrhythmia" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Ventricular Tachyarrhythmia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Control</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Control)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Second primary malignant neoplasm (10%; grades ≥3: 2%; including carcinoma [non-skin] and skin carcinoma [nonmelanoma])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular disease (1%; including cerebral ischemia, cerebrovascular accident, intracranial hemorrhage, ischemic stroke, subdural hematoma, transient ischemic attacks)<span class="lexi-table-link-container"> (<a aria-label="Cerebrovascular Disease table link" class="lexi-table-link" data-table-id="lexi-content-cerebrovascular-disease" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cerebrovascular-disease')">table 8</a>)</span><span class="table-link" style="display:none;">Cerebrovascular Disease</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cerebrovascular Disease" frame="border" id="lexi-content-cerebrovascular-disease" rules="all">
<caption style="text-align:center;">
<b>Ibrutinib: Adverse Reaction: Cerebrovascular Disease</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Control</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ibrutinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Control)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">958</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac conduction disorder (Salem 2019), cardiac tamponade (Kidoguchi 2021), cardiomyopathy (Kyi 2019), heart block (Vartanov 2021), sinoatrial arrest (Mathur 2017), supraventricular cardiac arrhythmia (Salem 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (Ghasoub 2020), dermatologic disorder (neutrophilic dermatoses), ecthyma (Ghasoub 2020), lichenoid eruption (Reji 2022), maculopapular rash (Jensen 2017), nail disease (including onychoclasis, onychomadesis, paronychia, pyogenic granuloma [periungual]) (Alamri 2022), pityriasis rosacea (Bitar 2017), pyoderma gangrenosum (Sławińska 2016), Stevens-Johnson syndrome, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (Burger 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal platelet aggregation (Kamel 2015), hemophagocytic lymphohistiocytosis (Ambinder 2019), tumor lysis syndrome (Ozturk 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic cirrhosis, hepatic failure (Kleijwegt 2019), hepatotoxicity (Nandikolla 2017, Tafesh 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy (Shaikh 2019), progressive multifocal leukoencephalopathy (Hsiehchen 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Panniculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cystoid macular edema (Ben-Avi 2022), uveitis (Bohn 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (including acute interstitial nephritis) (Markoth 2021), acute renal tubular disease (Manohar 2019), renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hemothorax (Wong 2022), interstitial lung disease, pneumonia due to <i>Pneumocystis jirovecii (</i>de Weerdt 2017), pneumonitis (Mato 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Serositis (Styskel 2019)</p></div>
<div class="block coi drugH1Div" id="F22688546"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Known hypersensitivity to ibrutinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F22802161"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause dizziness, fatigue, and/or weakness, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Diarrhea has been commonly observed; maintain adequate hydration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Anemia (all grades), thrombocytopenia, pneumonia (≥ grade 3), hypertension, and atrial fibrillation occurred more frequently in patients ≥65 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">• Waldenström macroglobulinemia: Hyperviscosity may require plasmapheresis prior to or during ibrutinib treatment in patients with Waldenström macroglobulinemia; adjustment of ibrutinib dose due to plasmapheresis is not necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Adherence: A retrospective analysis of a phase 3 efficacy trial in previously treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma evaluated the effect of dose intensity on progression-free survival (PFS) and overall response rate (ORR). A higher dose intensity was associated with longer median PFS and a higher ORR; optimal outcomes were achieved in patients with sustained adherence to a 420 mg/day dosing schedule (Barr 2017).</p></div>
<div class="block foc drugH1Div" id="F22769661"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imbruvica: 70 mg, 140 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imbruvica: 70 mg/mL (108 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imbruvica: 140 mg, 280 mg, 420 mg, 560 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F22769659"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F23613369"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Imbruvica Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $680.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">140 mg (per each): $226.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Imbruvica Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg/mL (per mL): $113.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Imbruvica Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">140 mg (per each): $680.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">280 mg (per each): $680.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420 mg (per each): $680.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871684"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imbruvica: 140 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imbruvica: 70 mg/mL (150 mL) [contains benzyl alcohol]</p></div>
<div class="block adm drugH1Div" id="F22802484"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Capsules and tablets: Administer with a glass of water at approximately the same time each day. Swallow capsules or tablets whole. Do not open, break, or chew capsules; do not cut, crush, or chew tablets. Maintain adequate hydration during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Based on an analysis of 3 pharmacokinetic studies, it is suggested that ibrutinib may be administered without regard to food (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25724156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25724156'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Ibrutinib was administered via NG and percutaneous endoscopic gastrostomy tube (single case report) by opening the capsule contents and flushing the contents down the tube(s) with water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Maddox.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Maddox.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">When administering ibrutinib in combination with rituximab or obinutuzumab, consider administering ibrutinib prior to rituximab or obinutuzumab when given on the same day.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Bottle is supplied with 2 reusable oral dosing syringes. Use only the oral dosing syringes that are supplied with ibrutinib suspension, do not use syringes for other patients or from other medications; do not use a household teaspoon (overdosage may occur). Shake well before use. Do not remove the bottle adapter. When measuring dose, remove air bubbles to ensure correct dose. Administer as soon as possible after withdrawing dose from bottle. Administer water after the ibrutinib suspension dose. Following administration, rinse oral syringe with water and let air-dry (do not use soap to clean; do not put in dishwasher). Refer to manufacturer’s instructions for more details.</p></div>
<div class="block admp drugH1Div" id="F57211440"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:<b></b>Administer with a glass of water at approximately the same time each day. Maintain adequate hydration during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules/tablets: Swallow capsules or tablets whole. Do not open, break, or chew capsules; do not cut, crush, or chew tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: With first use, document 60 days from opening as the discard date on the container. Shake well before use; attached bottle adapter should not be removed and may be wiped with a disposable tissue; use provided oral syringes to measure dose (if air bubble[s], pull plunger back a bit and tap side of syringe to remove air bubbles); squirt dose along inside of mouth along cheek; follow dose with a glass of water. After use, rinse oral syringe with water only and let air dry; do not clean with soap or in the dishwasher.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose</i>: Administer as soon as the missed dose is remembered on the same day; return to normal scheduling the following day. Do not take extra doses to make up for the missed dose.</p></div>
<div class="block use drugH1Div" id="F22688545"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic graft-versus-host disease, refractory: </b>Treatment of chronic graft-versus-host disease in adults and pediatric patients ≥1 year of age after failure of ≥1 lines of systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia/small lymphocytic lymphoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of CLL/SLL in adults with 17p deletion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia:</b> Treatment of Waldenström macroglobulinemia in adults.</p></div>
<div class="block mst drugH1Div" id="F22797741"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ibrutinib may be confused with acalabrutinib, avapritinib, Ibrance, ibritumomab, idelalisib, imatinib, ivosidenib, zanubrutinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) included among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F22813084"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F22813081"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Ibrutinib may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Ibrutinib may enhance the adverse/toxic effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bitter Orange: May increase the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Ibrutinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ibrutinib. Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ibrutinib. Management: Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for 7 days or less), interrupt ibrutinib therapy until the strong CYP3A4 inhibitor is discontinued.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Ibrutinib may enhance the anticoagulant effect of Dabigatran Etexilate. Ibrutinib may increase the serum concentration of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Ibrutinib may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flaxseed Oil: May enhance the adverse/toxic effect of Ibrutinib. Specifically, the risk for bleeding events may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Ibrutinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Ibrutinib may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Ibrutinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of Ibrutinib. Management: Ibrutinib dose reductions are required when combined with posaconazole. Dose recommendations depend on the indication for ibrutinib, age of the patient, and the posaconazole dose. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Ibrutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Ibrutinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Ibrutinib. Management: Ibrutinib dose reductions are required when combined with voriconazole. Dose recommendations depend on the indication for ibrutinib, age of the patient, and the voriconazole dose. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F22802463"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit and Seville oranges inhibit CYP3A (moderately or strongly) and may increase ibrutinib exposure. Management: Avoid grapefruit and Seville oranges during therapy.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307708"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 1 month after the last ibrutinib dose; patients with partners who could become pregnant should use effective contraception during treatment and for 1 month after the last ibrutinib dose.</p></div>
<div class="block pri drugH1Div" id="F22797744"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, ibrutinib may cause fetal harm if administered during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F22797746"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ibrutinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 week after the last ibrutinib dose.</p></div>
<div class="block dic drugH1Div" id="F22802483"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Avoid grapefruit, grapefruit juice, and Seville oranges during therapy.</p></div>
<div class="block mop drugH1Div" id="F22802486"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor blood counts monthly or as clinically necessary; renal and hepatic function; uric acid levels as clinically necessary. Verify pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor BP. Evaluate cardiac history/function at baseline; monitor cardiac function and for cardiac arrhythmias as clinically indicated, and monitor for signs/symptoms of cardiac arrhythmias and/or heart failure; obtain further evaluation (ECG or echocardiogram) as clinically indicated in patients who develop signs/symptoms of arrhythmias. Assess baseline risk for tumor lysis syndrome. Monitor for sign/symptoms of bleeding, infections/fever, progressive multifocal encephalopathy, tumor lysis syndrome, and/or second primary malignancies. Monitor for signs of leukostasis, particularly in patients experiencing a rapid increase in lymphocytes to &gt;400,000/mcL. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Assess BP at baseline and each clinical visit (as well as weekly home monitoring for initial 3 months), obtain ECG at each clinical visit, obtain a baseline echocardiography (transthoracic preferred) in high-risk patients; echocardiography is also recommended in all patients who develop atrial fibrillation (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F22802465"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ibrutinib is a potent and irreversible inhibitor of Bruton's tyrosine kinase (BTK), an integral component of the B-cell receptor (BCR) and cytokine receptor pathways. Constitutive activation of B-cell receptor signaling is important for survival of malignant B-cells; BTK inhibition results in decreased malignant B-cell proliferation and survival.</p></div>
<div class="block phk drugH1Div" id="F22802467"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Adults: V<sub>d</sub>: 683 L; V<sub>dss</sub>/F: ~10,000 L (Marostica 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Absolute bioavailability in fasted condition was 2.9% and doubled when combined with a meal. Administration with a high-fat, high-calorie meal (800 to 1,000 calories with ~50% of caloric content from fat) increased the C<sub>max</sub> by ~2- to 4-fold and the AUC 2-fold (compared with overnight fasting). Administration under fasting conditions resulted in exposure of ~60% compared to when administered either 30 minutes before or after a meal, or 2 hours after a high-fat meal (de Jong 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A (major) and CYP2D6 (minor) to active metabolite PCI-45227.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Adults: 1 to 2 hours (4 hours under fed conditions [de Jong 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (80%; 1% as unchanged drug); urine (&lt;10%, as metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance (apparent): Oral: Adults: 2,000 L/hour (fasted); 1,000 L/hour (fed).</p></div>
<div class="block phksp drugH1Div" id="F51159812"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC was increased 2.7-, 8.2-, and 9.8-fold, respectively, (C<sub>max</sub> was increased 5.2-, 8.8-, and 7-fold, respectively) in subjects with mild (Child-Pugh class A), moderate (Child-Pugh class B), or severe (Child-Pugh class C) hepatic impairment compared with subjects with normal hepatic function in a single-dose hepatic impairment trial.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27529528"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ibrutix | Imbruvica</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Binap | Brocabe | Brunitib | Ibruleu | Ibrutinex | Imbruvica | Plifosir | Vilanor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ibrucent | Ibruxen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ibrunat | Imbruvica | Nitib</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Notafol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Imbruvika</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Imbruvica</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27503501">
<a name="27503501"></a>Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. <i>Blood</i>. 2016;128(15):1940-1943.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/27503501/pubmed" id="27503501" target="_blank">27503501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36712781">
<a name="36712781"></a>Alamri A, Alghamdi Y, Alghamdi A, Albogami DB, Shahada O, AlHarbi A. Ibrutinib-induced paronychia and periungual pyogenic granuloma. <i>Cureus</i>. 2022;14(12):e32943. doi:10.7759/cureus.32943<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/36712781/pubmed" id="36712781" target="_blank">36712781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31400009">
<a name="31400009"></a>Ambinder AJ, Hambley B, Shanbhag S, Merrill SA. Ibrutinib-associated hemophagocytic lymphohistiocytosis: a case series from Johns Hopkins. <i>Am J Hematol</i>. 2019;94(11):E296-E299. doi:10.1002/ajh.25611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31400009/pubmed" id="31400009" target="_blank">31400009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28508526">
<a name="28508526"></a>Aw A, Hellman JM, Birner A, Davids MS. A complex case of ibrutinib treatment for a CLL patient on haemodialysis. <i>Br J Haematol.</i> 2018;181(6):854-857. doi:10.1111/bjh.14718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28508526/pubmed" id="28508526" target="_blank">28508526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28373262">
<a name="28373262"></a>Barr PM, Brown JR, Hillmen O, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i>. 2017;129(19):2612-2615. doi:10.1182/blood-2016-12-737346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28373262/pubmed" id="28373262" target="_blank">28373262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35243171">
<a name="35243171"></a>Ben-Avi R, Dori D, Chowers I. Cystoid macular edema secondary to ibrutinib. <i>Am J Ophthalmol Case Rep</i>. 2022;26:101436. doi:10.1016/j.ajoc.2022.101436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/35243171/pubmed" id="35243171" target="_blank">35243171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27649938">
<a name="27649938"></a>Bennett CL, Berger JR, Sartor O, et al. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. <i>Br J Haematol</i>. 2018;180(2):301-304. doi:10.1111/bjh.14322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/27649938/pubmed" id="27649938" target="_blank">27649938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29387749">
<a name="29387749"></a>Bitar C, Sadeghian A, Sullivan L, Murina A. Ibrutinib-associated pityriasis rosea-like rash. <i>JAAD Case Rep</i>. 2017;4(1):55-57. doi:10.1016/j.jdcr.2017.06.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/29387749/pubmed" id="29387749" target="_blank">29387749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33719653">
<a name="33719653"></a>Bohn M, Bravo-Ljubetic L, Lee RWJ, Petrushkin H. Ibrutinib-related uveitis: a report of two severe cases. <i>Eur J Ophthalmol</i>. 2022;32(4):NP94-NP97. doi:10.1177/11206721211001268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/33719653/pubmed" id="33719653" target="_blank">33719653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32704159">
<a name="32704159"></a>Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. <i>Leukemia</i>. 2020;34(12):3197-3205. doi:10.1038/s41375-020-0987-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/32704159/pubmed" id="32704159" target="_blank">32704159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26639149">
<a name="26639149"></a>Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>N Engl J Med</i>. 2015;373(25):2425-2437. doi:10.1056/NEJMoa1509388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26639149/pubmed" id="26639149" target="_blank">26639149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24881631">
<a name="24881631"></a>Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>N Engl J Med</i>. 2014;371(3):213-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/24881631/pubmed" id="24881631" target="_blank">24881631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23782158">
<a name="23782158"></a>Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. <i>N Engl J Med</i>. 2013;369(1):32-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/23782158/pubmed" id="23782158" target="_blank">23782158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26655421">
<a name="26655421"></a>Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncol</i>. 2016;17(2):200-211. doi:10.1016/S1470-2045(15)00465-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26655421/pubmed" id="26655421" target="_blank">26655421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25724156">
<a name="25724156"></a>de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. <i>Cancer Chemother Pharmacol</i>. 2015;75(5):907-916. doi:10.1007/s00280-015-2708-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25724156/pubmed" id="25724156" target="_blank">25724156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28775119">
<a name="28775119"></a>de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. <i>Haematologica</i>. 2017;102(10):1629-1639. doi:10.3324/haematol.2017.164103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28775119/pubmed" id="28775119" target="_blank">28775119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31582362">
<a name="31582362"></a>Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. <i>Blood</i>. 2019;134(22):1919-1928. doi:10.1182/blood.2019000840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31582362/pubmed" id="31582362" target="_blank">31582362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29856685">
<a name="29856685"></a>Dimopoulos MA, Tedeschi A, Trotman J, et al; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. <i>N Engl J Med</i>. 2018;378(25):2399-2410. doi:10.1056/NEJMoa1802917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/29856685/pubmed" id="29856685" target="_blank">29856685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29071051">
<a name="29071051"></a>Filanovsky K, Shvidel L. Safety and efficacy of ibrutinib in a patient with severe renal impairment. <i>Hematol Rep</i>. 2017;9(3):7078. doi:10.4081/hr.2017.7078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/29071051/pubmed" id="29071051" target="_blank">29071051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31216242">
<a name="31216242"></a>Ghasoub R, Albattah A, Elazzazy S, et al. Ibrutinib-associated sever skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - case report and literature review. <i>J Oncol Pharm Pract</i>. 2020;26(2):487-491. doi:10.1177/1078155219856422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31216242/pubmed" id="31216242" target="_blank">31216242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30045034">
<a name="30045034"></a>Hsiehchen D, Arasaratnam R, Raj K, Froehlich T, Anderson L. Ibrutinib use complicated by progressive multifocal leukoencephalopathy. <i>Oncology</i>. 2018;95(5):319-322. doi:10.1159/000490617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/30045034/pubmed" id="30045034" target="_blank">30045034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imbruvica.1">
<a name="Imbruvica.1"></a>Imbruvica (ibrutinib) [prescribing information]. South San Francisco, CA: Pharmacyclics LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imbruvica.2">
<a name="Imbruvica.2"></a>Imbruvica (ibrutinib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28469834">
<a name="28469834"></a>Jensen AB, Stausbøl-Grøn B, Riber-Hansen R, d'Amore F. Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstrom's macroglobulinemia and review of the literature. <i>Dermatol Reports</i>. 2017;9(1):6976. doi:10.4081/dr.2017.6976<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28469834/pubmed" id="28469834" target="_blank">28469834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138588">
<a name="25138588"></a>Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. <i>Leukemia</i>. 2015;29(4):783-787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25138588/pubmed" id="25138588" target="_blank">25138588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138588">
<a name="25138588"></a>Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. <i>NEJM Evidence</i>. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200006. Published May 13, 2022. Accessed May 26, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25138588/pubmed" id="25138588" target="_blank">25138588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33161683">
<a name="33161683"></a>Kidoguchi K, Kubato Y, Nishimura Y, Kizuka-Sano H, Kimura S. Ibrutinib-induced cardiac tamponade in chronic lymphocytic leukemia. <i>Turk J Haematol</i>. 2021;38(1):83-85. doi:10.4274/tjh.galenos.2020.2020.0446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/33161683/pubmed" id="33161683" target="_blank">33161683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31976481">
<a name="31976481"></a>Kleijwegt FS, Roda AA, Rolvink J, Kater AP, Kersten MJ, Vos JMI. Rare but serious: ibrutinib induced liver failure. <i>Hemasphere</i>. 2019;3(6):e307. doi:10.1097/HS9.0000000000000307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31976481/pubmed" id="31976481" target="_blank">31976481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30788077">
<a name="30788077"></a>Kyi HH, Zayed Y, Al Hadidi S. Ibrutinib-induced cardiomyopathy. <i>J Community Hosp Intern Med Perspect</i>. 2019;9(1):50-52. doi:10.1080/20009666.2018.1555432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/30788077/pubmed" id="30788077" target="_blank">30788077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28223277">
<a name="28223277"></a>Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i>. 2017;129(18):2581-2584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28223277/pubmed" id="28223277" target="_blank">28223277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26430171">
<a name="26430171"></a>Lipsky AH, Farooqui MZ, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i>. 2015;100(12):1571-1578. doi:10.3324/haematol.2015.126672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26430171/pubmed" id="26430171" target="_blank">26430171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27456945">
<a name="27456945"></a>Lutz M, Schulze AB, Rebber E, et al. Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. <i>Cancer Res Treat</i>. 2017;49(2):548-552. doi:10.4143/crt.2016.110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/27456945/pubmed" id="27456945" target="_blank">27456945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maddox.1">
<a name="Maddox.1"></a>Maddox JM, Majid M. Use of ibrutinib via nasogastric (NG) tube &amp; percutaneous endoscopic gastrostomy (PEG) tube. <i>Blood</i>. 2016;128(22):5371 [abstract from 2016 American Society of Hematology annual meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31148235">
<a name="31148235"></a>Manohar S, Bansal A, Wanchoo R, Sakhiya V, Lucia S, Jhaveri KD. Ibrutinib induced acute tubular injury: a case series and review of the literature. <i>Am J Hematol</i>. 2019;94(9):E223-E225. doi:10.1002/ajh.25546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31148235/pubmed" id="31148235" target="_blank">31148235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33567947">
<a name="33567947"></a>Markóth C, File I, Szász R, Bidiga L, Balla J, Mátyus J. Ibrutinib-induced acute kidney injury via interstitial nephritis. <i>Ren Fail</i>. 2021;43(1):335-339. doi:10.1080/0886022X.2021.1874985<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/33567947/pubmed" id="33567947" target="_blank">33567947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25381051">
<a name="25381051"></a>Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. <i>Cancer Chemother Pharmacol</i>. 2015;75(1):111-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25381051/pubmed" id="25381051" target="_blank">25381051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29375920">
<a name="29375920"></a>Mathur K, Saini A, Ellenbogen KA, Shepard RK. Profound sinoatrial arrest associated with ibrutinib. <i>Case Rep Oncol Med</i>. 2017;2017:7304021. doi:10.1155/2017/7304021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/29375920/pubmed" id="29375920" target="_blank">29375920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26702066">
<a name="26702066"></a>Mato AR, Islam P, Daniel C, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. <i>Blood</i>. 2016;127(8):1064-1067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/26702066/pubmed" id="26702066" target="_blank">26702066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924018">
<a name="28924018"></a>Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i>. 2017;130(21):2243-2250. doi:10.1182/blood-2017-07-793786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28924018/pubmed" id="28924018" target="_blank">28924018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522969">
<a name="30522969"></a>Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2019;20(1):43-56. doi:10.1016/S1470-2045(18)30788-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/30522969/pubmed" id="30522969" target="_blank">30522969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28588800">
<a name="28588800"></a>Nandikolla AG, Derman O, Nautsch D, et al. Ibrutinib-induced severe liver injury. <i>Clin Case Rep</i>. 2017;5(6):735-738. doi:10.1002/ccr3.881<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28588800/pubmed" id="28588800" target="_blank">28588800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36278298">
<a name="36278298"></a>Ohtani T, Tani A, Namme Y, et al. Pharmacokinetics of ibrutinib in a patient with chronic lymphocytic leukemia on hemodialysis. <i>Clin Nephrol</i>. 2022;98(6):301-304. doi:10.5414/CN110859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/36278298/pubmed" id="36278298" target="_blank">36278298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34239769">
<a name="34239769"></a>Ozturk E, Erdogan Ozunal I. A rare side effect of ibrutinib: tumor lysis syndrome. <i>Medeni Med J</i>. 2021;36(2):176-179. doi:10.5222/MMJ.2021.56424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/34239769/pubmed" id="34239769" target="_blank">34239769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35371696">
<a name="35371696"></a>Reji M, Shah KK. A novel finding of lichenoid drug reaction from ibrutinib therapy. <i>Cureus</i>. 2022;14(2):e22433. doi:10.7759/cureus.22433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/35371696/pubmed" id="35371696" target="_blank">35371696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31558250">
<a name="31558250"></a>Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. <i>J Am Coll Cardiol</i>. 2019;74:1667-1678. doi:10.1016/j.jacc.2019.07.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31558250/pubmed" id="31558250" target="_blank">31558250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25488930">
<a name="25488930"></a>Scheers E, Leclercq L, de Jong J, et al. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. <i>Drug Metab Dispos.</i> 2015;43(2):289-297. doi:10.1124/dmd.114.060061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25488930/pubmed" id="25488930" target="_blank">25488930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30045682">
<a name="30045682"></a>Shaikh H, Khattab A, Faisal MS, et al. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. <i>J Oncol Pharm Pract</i>. 2019;25(5):1265-1270. doi:10.1177/1078155218788707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/30045682/pubmed" id="30045682" target="_blank">30045682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35427411">
<a name="35427411"></a>Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i>. 2022;140(2):112-120. doi:10.1182/blood.2021014960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/35427411/pubmed" id="35427411" target="_blank">35427411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31365801">
<a name="31365801"></a>Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. <i>N Engl J Med</i>. 2019;381(5):432-443. doi:10.1056/NEJMoa1817073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31365801/pubmed" id="31365801" target="_blank">31365801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27698335">
<a name="27698335"></a>Sławińska M, Barańska-Rybak W, Sobjanek M, Wilkowska A, Mital A, Nowicki R. Ibrutinib-induced pyoderma gangrenosum. <i>Pol Arch Med Wewn</i>. 2016;126(9):710-711. doi:10.20452/pamw.3578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/27698335/pubmed" id="27698335" target="_blank">27698335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30802411">
<a name="30802411"></a>Styskel BA, Lopez-Mattei J, Jimenez CA, Stewart J, Hagemeister FB, Faiz SA. Ibrutinib-associated serositis in mantle cell lymphoma. <i>Am J Respir Crit Care Med</i>. 2019;199(12):e43-e44. doi:10.1164/rccm.201809-1738IM<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/30802411/pubmed" id="30802411" target="_blank">30802411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31607836">
<a name="31607836"></a>Tafesh ZH, Coleman M, Fulmer C, Nagler J. Severe hepatotoxicity due to ibrutinib with a review of published cases. <i>Case Rep Gastroenterol</i>. 2019;13(2):357-363. doi:10.1159/000502605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/31607836/pubmed" id="31607836" target="_blank">31607836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28714377">
<a name="28714377"></a>Titus-Rains KS, Brown JN, Hammond JM. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: a case series and review of the literature. <i>J Oncol Pharm Pract.</i> 2018;24(7):544-549. doi:10.1177/1078155217718617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/28714377/pubmed" id="28714377" target="_blank">28714377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32931398">
<a name="32931398"></a>Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. <i>J Clin Oncol</i>. 2021;39(6):565-575. doi:10.1200/JCO.20.00555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/32931398/pubmed" id="32931398" target="_blank">32931398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25853747">
<a name="25853747"></a>Treon SP, Tripsas CK, Meid K et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. <i>N Engl J Med</i>. 2015;372(15):1430-1440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/25853747/pubmed" id="25853747" target="_blank">25853747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34194987">
<a name="34194987"></a>Vartanov AR, Lampson BL, Jacobsen ED, Alyea EP, Moslehi JJ, Brown JR. High-grade heart block associated with ibrutinib therapy. <i>HeartRhythm Case Rep</i>. 2021;7(6):391-394. doi:10.1016/j.hrcr.2021.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/34194987/pubmed" id="34194987" target="_blank">34194987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34618601">
<a name="34618601"></a>Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. <i>J Clin Oncol</i>. 2021;39(34):3853-3865. doi:10.1200/JCO.21.00807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/34618601/pubmed" id="34618601" target="_blank">34618601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36467786">
<a name="36467786"></a>Wong JSY, Sadullah S. Acute haemothorax secondary to ibrutinib: a case report. <i>EJHaem</i>. 2022;3(4):1365-1366. doi:10.1002/jha2.367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/36467786/pubmed" id="36467786" target="_blank">36467786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24415539">
<a name="24415539"></a>Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i>. 2014;123(12):1810-1817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/24415539/pubmed" id="24415539" target="_blank">24415539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33938097">
<a name="33938097"></a>Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review.<i> Cancer Sci.</i> 2021;112(7):2607-2624. doi:10.1111/cas.14933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ibrutinib-drug-information/abstract-text/33938097/pubmed" id="33938097" target="_blank">33938097</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 91587 Version 310.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
